KPTI News and Press, Karyopharm Therapeutics Inc. From 02/08/22

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer - Selinexor Demonstrates Statistically Significant 50% Improvement in Median Progressio...

Karyopharm Therapeutics (NASDAQ:KPTI) is scheduled to announce Q4 earnings results on Tuesday, February 8th, before market open. The consensus EPS Estimate is -$0.42 (+28.8% Y/Y) and the consensus Revenue Estimate is $31.92M (-9.1% Y/Y). Over the last 3 months, EPS estimates have seen 3 upwar...

AGCO, ARMK, AVNT, OTCQX:BNPQF, BP, CARR, CEIX, CNC, CNHI, COTY, CVE, DD, FISV, HAE, HLI, HOG, INCY, IT, J, KKR, KPTI, LEA, MAS, MBUU, MFGP, NRZ, OTCPK:NSANY, PFE, POLY, QTNT, OTCPK:SFTBY, SPGI, SQNS, SYY, TDG, TMHC, TRI, VIRT, VSH, WMG, WTW For Seeking Alpha's full earnings season calendar,&#...

Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022 -- Conference Call Scheduled for Tuesday, February 8, 2022, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , Feb. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (...

Karyopharm Therapeutics (NASDAQ:KPTI) granted 15 newly-hired employees stock options to buy a total of 124.5K common shares. The stock options were granted as inducements material and have an exercise price of $8.90 per share. For further details see: Karyopharm grants st...

Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes PR Newswire NEWTON, Mass. , Jan. 24, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pion...

Karyopharm to Present at B. Riley Securities Oncology Investor Conference PR Newswire NEWTON, Mass. , Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today anno...

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer PR Newswire NEWTON, Mass. , Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced t...

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives - Unaudited Net Product Revenues of Approximately $29.7 Million for Fourth Quarter 2021 and Approximately $98.3 Million for the Full Year 2021- - Co...

Karyopharm to Present at 40th Annual J.P. Morgan Healthcare Conference PR Newswire NEWTON, Mass. , Jan. 4, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announce...